Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, August 9 '25)

Image
By G.M.

 


    Antimicrob Agents Chemother

  1. HARFOOT R, Lawley B, Hernandez LC, Kuang J, et al
    Synthetic host defense peptide inhibits SARS-CoV-2 replication in vitro.
    Antimicrob Agents Chemother. 2025;69:e0170024.
    PubMed         Abstract available

  2. TATE M, Illingworth CJR, MacGregor G, Cunningham L, et al
    Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial.
    Antimicrob Agents Chemother. 2025;69:e0005425.
    PubMed         Abstract available

  3. ZHOU Y, Meng X, Li J, Zeng G, et al
    Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants.
    Antimicrob Agents Chemother. 2025;69:e0056825.
    PubMed         Abstract available

  4. GOMI S, Price E, Burgoyne H, Faozia S, et al
    Omadacycline exhibits anti-inflammatory properties and improves survival in a murine model of post-influenza MRSA pneumonia.
    Antimicrob Agents Chemother. 2025 Aug 4:e0046925. doi: 10.1128/aac.00469.
    PubMed         Abstract available


    BMC Pediatr

  5. LEE Y, Choi H, Son Y
    Problematic smartphone use and risk behaviors in adolescents during the COVID-19 pandemic.
    BMC Pediatr. 2025;25:590.
    PubMed         Abstract available


    Drugs

  6. KEAM SJ
    Sipavibart: First Approval.
    Drugs. 2025;85:1049-1054.
    PubMed         Abstract available


    J Gen Virol

  7. BREITINGER U, Zakaria ZIS, Mahgoub HA, Wiessler AL, et al
    Activity and cellular distribution of ORF3a mutants of SARS-CoV-2 variants of concern.
    J Gen Virol. 2025;106:002135.
    PubMed         Abstract available


    J Virol

  8. SOWNTHIRARAJAN B, Mason M, Loganathan G, Manivasagam S, et al
    A versatile H5N1-VSV platform for safe influenza virus research applications.
    J Virol. 2025 Aug 8:e0097525. doi: 10.1128/jvi.00975.
    PubMed         Abstract available

  9. LIU Z, Zhang L, Zhang W, Lai Y, et al
    The 5'-end segment-specific noncoding region of influenza A virus regulates both competitive multi-segment RNA transcription and selective genome packaging during infection.
    J Virol. 2025 Aug 5:e0032825. doi: 10.1128/jvi.00328.
    PubMed         Abstract available

  10. MBOKO WP, Wang Y, Cao W, Sayedahmed EE, et al
    Trained ILCs confer adaptive immunity-independent protection against influenza.
    J Virol. 2025 Aug 4:e0053225. doi: 10.1128/jvi.00532.
    PubMed         Abstract available

  11. ZANIN M, Flerlage T, Wong S-S, Vogel P, et al
    Inflammatory, transcriptomic, and cell fate responses underlying the mammalian transmission of avian influenza viruses.
    J Virol. 2025 Aug 8:e0064725. doi: 10.1128/jvi.00647.
    PubMed         Abstract available


    J Virol Methods

  12. WANG P, Yan L, Wang J, Hu S, et al
    Utilizing multiplex reverse transcription-multiple cross displacement amplification-lateral flow biosensor technology for detecting H1N1, H3N2 and H7N9 influenza A virus subtypes.
    J Virol Methods. 2025;338:115235.
    PubMed         Abstract available


    PLoS One

  13. ZHU Z, Gao G, Hu Y, Zhao X, et al
    Impact of ventilation and ambient temperature on COVID-19 transmission in clinic waiting rooms: A computational fluid dynamics approach.
    PLoS One. 2025;20:e0328154.
    PubMed         Abstract available

  14. SUZUKI K, Mizuno Y, Arai Y, Miyamura K, et al
    Longitudinal association between psychological distress and mask-wearing post COVID-19 among psychiatric outpatients in Japan.
    PLoS One. 2025;20:e0329644.
    PubMed         Abstract available

  15. FANSHAWE TR, Tonner S, Turner PJ, Glogowska M, et al
    Diagnostic accuracy evaluation of a point-of-care antigen test for SARS-CoV-2 and influenza in UK primary care (RAPTOR-C19).
    PLoS One. 2025;20:e0329611.
    PubMed         Abstract available

  16. KEELAPANG N, Sunkonkit K
    Factors associated with intubation and heated high-flow nasal cannula use in hospitalized respiratory syncytial virus infected children: A single-center retrospective cohort study.
    PLoS One. 2025;20:e0327541.
    PubMed         Abstract available

  17. KOKELJ S, Larsson P, Viklund E, Koca H, et al
    Changes in the pulmonary surfactant in patients with mild to moderate COVID-19.
    PLoS One. 2025;20:e0325153.
    PubMed         Abstract available

  18. JANSSEN MF, Rand K, Estevez-Carrillo A, Ramos-Goni JM, et al
    Health-related quality of life and QALY loss under COVID-19 lockdown: The case of Spain.
    PLoS One. 2025;20:e0329413.
    PubMed         Abstract available

  19. SHOJI M, Nakaoka K, Ishikawa M, Kasai Y, et al
    Triethylamine inhibits influenza A virus infection and growth via mechanisms independent of viral neuraminidase and RNA-dependent RNA polymerase.
    PLoS One. 2025;20:e0329964.
    PubMed         Abstract available

  20. DICKERSON SS, Larkin KP, Loomis D, Tyrpak D, et al
    Utilizing an explanatory case method approach to explore alternative recruitment strategies for a longitudinal randomized clinical trial of insomnia treatment in cancer survivors amid COVID-19.
    PLoS One. 2025;20:e0327806.
    PubMed         Abstract available

  21. ECKLER R, Fayek B, Won E, Dobrer S, et al
    Impact of the COVID-19 pandemic on pregnancy complications and conceptions resulting in births following spontaneous conception and in-vitro fertilization in British Columbia: A population-based study.
    PLoS One. 2025;20:e0329683.
    PubMed         Abstract available

  22. AMBERGER O, Lemke D, Muller H, Schwappach D, et al
    Trends in public perceptions of patient safety during the COVID-19 pandemic: Findings from a repeated cross-sectional survey in Germany, 2019-2023.
    PLoS One. 2025;20:e0329761.
    PubMed         Abstract available

  23. NGUYEN NT, Nguyen NP, Truong QT, Huynh TP, et al
    Healthcare utilization associated with antimicrobial resistance at a tertiary hospital in Vietnam: A retrospective observational study from 2016 to 2021.
    PLoS One. 2025;20:e0329539.
    PubMed         Abstract available

  24. MATHIAS H, Jackson LA, Buxton JA, Dube A, et al
    Features of drug addiction treatment programs in Atlantic Canada that help (or not) with access and retention: A qualitative study.
    PLoS One. 2025;20:e0328524.
    PubMed         Abstract available

  25. MARTINEZ-BORBA V, Peris-Baquero O, Prieto-Rollan I, Osma J, et al
    Preliminary feasibility and clinical utility of the Unified Protocol for the transdiagnostic treatment of emotional disorders in people with long COVID-19 condition: A single case pilot study.
    PLoS One. 2025;20:e0329595.
    PubMed         Abstract available

  26. CRUZ-CANO R, Payne-Sturges DC
    Emergency temporary standards and COVID-19 trends among Oregon farmworkers.
    PLoS One. 2025;20:e0329130.
    PubMed         Abstract available

  27. MOHAMED PAUZI MH, Abdul Kadir A, Muhamad R, Mat Yudin Z, et al
    A qualitative study on barriers and facilitators of COVID-19 vaccination during pregnancy among pregnant women in Malaysia.
    PLoS One. 2025;20:e0329895.
    PubMed         Abstract available

  28. GUGGILLA V, Pacheco JA, Carvalho AM, Whitmer GR, et al
    Immunosuppression variably impacts outcomes for patients hospitalized with COVID-19: A retrospective cohort study.
    PLoS One. 2025;20:e0330110.
    PubMed         Abstract available

  29. KHAN AH, Li J, Asghar MN, Iqbal S, et al
    LGD_Net: Capsule network with extreme learning machine for classification of lung diseases using CT scans.
    PLoS One. 2025;20:e0327419.
    PubMed         Abstract available

  30. WOODWARD ML, Wolsey MW, Shalchy-Tabrizi S, Bone JN, et al
    Assessment of change and persistence of youth psychosocial status reported by youth and their guardians during the COVID-19 pandemic: A MyHEARTSMAP study.
    PLoS One. 2025;20:e0329898.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  31. ASLAM S, Sanchez-Aparicio MT, Siempelkamp BD, Dornan GL, et al
    Influenza A virus NS1 protein mimics oncogenic PI3K resulting in isoform specific cellular redistribution and activation.
    Proc Natl Acad Sci U S A. 2025;122:e2423066122.
    PubMed         Abstract available

  32. MCGUIRE DJ, Akondy RS, Yang S, Edupuganti S, et al
    Regulation of CD45 isoforms during human effector and memory CD8 T cell differentiation: Implications for T cell nomenclature.
    Proc Natl Acad Sci U S A. 2025;122:e2322982122.
    PubMed         Abstract available

  33. HSU CC, Chamblee M, Ye C, Shamseldin MM, et al
    Intranasal measles virus- and mumps virus-based SARS-CoV-2 vaccine candidates prevent SARS-CoV-2 infection and transmission.
    Proc Natl Acad Sci U S A. 2025;122:e2506821122.
    PubMed         Abstract available

  34. LYU L, Gill M, Stott G, Subedi S, et al
    Tracing SARS-CoV-2 clusters across local scales using genomic data.
    Proc Natl Acad Sci U S A. 2025;122:e2501435122.
    PubMed         Abstract available


    Vaccine

  35. CHOI WS, Lee J, Ottaviano C, Samson S, et al
    Immunogenicity and safety of quadrivalent recombinant influenza vaccine in Korean adults: Phase III, randomized study.
    Vaccine. 2025;62:127521.
    PubMed         Abstract available

  36. LIU R, Patel A, Liu H, Du X, et al
    Influenza vaccination in patients with heart failure compared to usual practice: A model-based cost-effectiveness analysis.
    Vaccine. 2025;62:127566.
    PubMed         Abstract available


    Virology

  37. EBRAHIMI N, Sadeh S, Ghaemi A
    Is HA0-Mediated heat resistance in influenza a food safety concern? A methodological critique.
    Virology. 2025 Jul 29:110643. doi: 10.1016/j.virol.2025.110643.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »